Interim Report Third Quarter 2019
FluoGuide A/S ("FluoGuide") today announces its results for the period 01/July/2019 – 30/Sep/2019. The full report is available on the company’s homepage.Morten Albrechtsen, CEO of FluoGuide, comments: “We are very pleased that the supply chain for FG001 has been established to support the first clinical study in humans and the process for FG001 manufacturing was successfully transferred to vendors who can make it to a quality needed for human use. This is good news and a major de-risking for a positive proof-of-concept clinical result in patients with glioblastoma undergoing surgery. Also,